NJT Stock Overview A clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
RegenETP, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for RegenETP Historical stock prices Current Share Price US$0.22 52 Week High US$0.99 52 Week Low US$0.20 Beta 0.86 1 Month Change 0% 3 Month Change 10.00% 1 Year Change -75.56% 3 Year Change -98.99% 5 Year Change -99.94% Change since IPO -99.99%
Recent News & Updates RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC May 21
PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers Feb 27 PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer PolarityTE, Inc. announced delayed 10-Q filing
PolarityTE, Inc. Files Form 15 Aug 12 Nasdaq to Delist the Common Stock of PolarityTE Jul 08
See more updates RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC May 21
PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers Feb 27 PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer PolarityTE, Inc. announced delayed 10-Q filing
PolarityTE, Inc. Files Form 15 Aug 12 Nasdaq to Delist the Common Stock of PolarityTE Jul 08
PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index Jun 17 PolarityTE's Common Stock To Be Delisted From Nasdaq
First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022) May 14
Forecast to breakeven in 2025 Mar 28
Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors Jan 28
Insufficient new directors Jan 19
Forecast to breakeven in 2025 Jan 04
Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021) Nov 12
Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE). Nov 10
PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq Oct 31
PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors Sep 09
Second quarter 2022 earnings released: US$0.013 loss per share (vs US$0.99 loss in 2Q 2021) Aug 13
PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 02
First quarter 2022 earnings released: US$0.045 loss per share (vs US$0.23 loss in 1Q 2021) May 17
PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R) May 14
PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022 May 07
Full year 2021 earnings released: US$0.38 loss per share (vs US$1.11 loss in FY 2020) Mar 31 PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone
PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent Feb 18
PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication Jan 19
PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application Dec 21
Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020) Nov 11
Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc Sep 29
Independent Director Minnie Baylor-Henry has left the company Sep 07
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE® Aug 25
PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Aug 18
Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020) Aug 14
Independent Chairman of the Board recently bought €212k worth of stock May 21
First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020) May 16
PolarityTE, Inc. Updates on SkinTE Biologic License Application May 15
PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint May 11
PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021 Mar 11
PolarityTE, Inc. Announces Submission of an Investigational New Drug Application Feb 11
New 90-day high: €1.23 Feb 10
PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial Jan 22
PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million. Jan 15
New 90-day high: €0.98 Jan 09
New 90-day low: €0.53 Dec 12
Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice Nov 25
New 90-day low: €0.57 Nov 24
Third quarter 2020 earnings released: US$0.18 loss per share Nov 11
Revenue beats expectations Nov 11
PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE® Nov 05
PolarityTE, Inc. to Report Q3, 2020 Results on Nov 09, 2020 Oct 27
New 90-day low: €0.82 Oct 22
PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds Sep 22
New 90-day low: €0.85 Sep 19
PolarityTE, Inc. Announces SkinTE™ Health Economics — DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure Sep 17
New 90-day low - €0.94 Sep 04
First half earnings released Aug 07
New 90-day high - €1.47 Jul 16 PolarityTE, Inc.(NasdaqCM:PTE) dropped from Russell Small Cap Completeness Index Shareholder Returns NJT DE Biotechs DE Market 7D 0% 5.5% 1.2% 1Y -75.6% -3.7% 10.1%
See full shareholder returns
Return vs Market: NJT underperformed the German Market which returned 5.9% over the past year.
Price Volatility Is NJT's price volatile compared to industry and market? NJT volatility NJT Average Weekly Movement n/a Biotechs Industry Average Movement 7.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: NJT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NJT's volatility change over the past year.
About the Company RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.
Show more RegenETP, Inc. Fundamentals Summary How do RegenETP's earnings and revenue compare to its market cap? NJT fundamental statistics Market cap €436.38k Earnings (TTM ) -€7.75m Revenue (TTM ) €68.13k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NJT income statement (TTM ) Revenue US$73.00k Cost of Revenue US$125.00k Gross Profit -US$52.00k Other Expenses US$8.25m Earnings -US$8.30m
Last Reported Earnings
Mar 31, 2023
Earnings per share (EPS) -1.15 Gross Margin -71.23% Net Profit Margin -11,376.71% Debt/Equity Ratio 0%
How did NJT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/09/12 00:50 End of Day Share Price 2023/06/15 00:00 Earnings 2023/03/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources RegenETP, Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jonathan Aschoff B. Riley Wealth Kristen Kluska Cantor Fitzgerald & Co. Joshua Schimmer Evercore ISI
Show 8 more analysts 
